Fluralaner is an isoxazoline class compound that is the only topically applied systemic ectoparasiticide approved for dosing at up to 12-week intervals for flea and tick control in dogs and cats.
Fluralaner can be administered at a reduced dosage using various routes: topical, oral, injectable.
For topical route, fluralaner can be administered for example through a collar, a smart collar, a tag, an impregnated device, a spot-on, a pour-on or a patch.
For oral route, fluralaner can be administered as a pet food (solid or liquid), treats, pastes, chews, tablets, in addition to drinking water or as a liquid to be poured directly in the mouth or on the food.
For injectable route, fluralaner can be administered as an implant, a biodegradable injectable implant (“depot implant”), an injection (s.c. or i.m.), a long acting injectable.
Side effects may include vomiting, diarrhea, decreased appetite, or flaky skin. More serious side effects include muscle tremors, seizures, incoordination, or severe upset stomach. Need to follow veterinarian’s description.
Fluralaner market is expected to witness significant growth in the coming years, primarily driven by the growing demand for (Veterinary Drug, Insecticide, Other).
The Global Fluralaner market is anticipated to rise at a considerable rate during the forecast period, between 2023 and 2030. In 2022, the market is growing at a steady rate and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.
Post time: Nov-22-2023